

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/693,480		
		Filing Date	October 23, 2003		
		First Named Inventor	Silviu Itescu		
		Art Unit	1635		
		Examiner Name	B.E. Bunner		
Sheet	2	of	4	Attorney Docket Number	66602-B/JPW/BJA/LM

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	International Search Report issued on August 24, 2004 in connection with corresponding International Application No. PCT/US03/12768, filed April 23, 2002	
	5	Bonaros et al. (2008), "CCR3- and CXCR4-mediated Interactions Regulate Migration of CD34+ Human Bone Marrow...Repair." J. Thor. Cardio. Surg., 136(4):1044-1053	
	6	Chavakis, E. (2006), "IL-8: A New Player in the Homing of Endothelial Progenitor Cells to Ischemic Myocardium." J. Mol. Cell. Cardiol. 40:442-445;	
	7	Janeway, et al. (1997), "Immunobiology: The Immune System in Health and Disease." NY: Current Biology Limited. 1:11-12	
	8	Khachigian, LM, (2000), "Catalytic DNAs as Potential Therapeutic Agents and Sequence-Specific Molecular Tools...Function." J. of Clin Investigation 106(10):1189-1195	
	9	Kocher, et al. (2006), "Myocardial Homing and Neovascularization by Human Bone Marrow Angioblasts is Regulated by IL-8/Gro CXC Chemokines." J. Mol. Cell. Cardiol. 40:455-464	
	10	Lefer, et al. (1991), "Cardioprotective and Endothelial Protective Effects of [Ala-IL8] 77 in a Rabbit Model of Myocardial...Reperfusion." Br. J. Pharmacol.103:1152-1159	
	11	Nishiyama, et al. (1999), "Identification of Thioredoxin-Binding Protein-2/Vitamin D3 Up-Regulated Protein 1 as a Negative Regulator of ..."J Biol. Chem. 274(31):21645-21650	
	12	Pak, J.H. et al. (2002), "An antisense Oligonucleotides to 1-cys Peroxiredoxin Causes Lipid Peroxidation and Apoptosis in Lung...Cells." J. Bio. Chem., 277(51):49927-49934	
	13	Park, S. et al. (2000), "Antisense of Human Peroxiredoxin II Enhances Radiation-Induced Cell Death." Clin. Cancer. Research, 6:4915-4920	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/693,480
Filing Date	October 23, 2003
First Named Inventor	Silviu Itescu
Art Unit	1635
Examiner Name	B.E. Bunner
Attorney Docket Number	66602-B/JPW/BJA/LM

Sheet 3

of

4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	14	Rinn, et al. (2006), "Anatomic Demarcation by Positional Variation in Fibroblast Gene Expression Programs." PLOS Genetics 2(7):1084-1096	
	15	UniprotKB/Swiss-Prot P10145 (IL_8HUMAN), www.uniprot/P10145. Last Modified May 26, 2009. Version 120	
	16	Wang, L. (2000), "ACE Inhibitors and Beta Blockers Equally Attenuate Ischemia-Induced Reduction in Ventricular...Threshold." Exp. Clin. Cardiol. 5(2):82-86	
	17	Xiang et al. 2005, Catalytic Degradation of Vitamin D Up-Regulated Protein 1 mRNA Enhances Cardiomyocytes Survival and Prevents Left Ventricula..." J Biol Chem 280(47):39394-3	
	18	March 10, 2006 Official Action issued in connection with corresponding Chinese Patent Application No. 03814715.7	✓
	19	April 29, 2008 Official Action issued in connection with corresponding Israeli Patent Application No. 164671	✓
	20	November 20, 2008 Final Office Action issued in connection with co-pending U.S. Serial No. 11/234,879	
	21	December 31, 2008 Office Action issued in connection with co-pending U.S. Serial No. 11/894,555	
	22	February 12, 2009 Office Action issued in connection with co-pending U.S. Serial No. 11/894,555	
	23	March 10, 2009 Office Action issued in connection with co-pending U.S. Serial No. 10/512,518	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Receipt date: 08/06/2009

10693480 - GAU: 1647

PTO/SB/08b (01-08)

Approved for use through 06/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/693,480
Filing Date	October 23, 2003
First Named Inventor	Silviu Itescu
Art Unit	1635
Examiner Name	B.E. Bunner
Attorney Docket Number	66602-B/JPW/BJA/LM

Sheet 4

of

4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	24	March 13, 2009 Office Action issued in connection with co-pending U.S. Serial No. 11/648,769	
	25	June 12, 2009 Office Action issued in connection with co-pending U.S. Serial No. 11/894,581	
	26	July 9, 2009 Notice of Allowance and Fee(s) Due issued in connection with co-pending U.S. Serial No. 11/234,879	

Examiner
Signature

/Bridget E. Bunner/

Date

Considered

09/09/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/